BackSilexion Therapeutics - Warrants(14/08/2029) Overview

Silexion Therapeutics - Warrants(14/08/2029) Other Current Assets

Track Silexion Therapeutics - Warrants(14/08/2029)'s other current assets ($1.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$1.51M
↓ 14.68% YoYΔ $-260000.00 vs prior year quarter

Peer average / median

Loading

Silexion Therapeutics - Warrants(14/08/2029) Other Current Assets History

Loading

Silexion Therapeutics - Warrants(14/08/2029) vs. peers: Other Current Assets Comparison

Loading

Silexion Therapeutics - Warrants(14/08/2029) Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Silexion Therapeutics - Warrants(14/08/2029) (SLXNW) FAQ

As of the most recent data (June 2026), SLXNW shows a other current assets of $1.5M. That compares with $1.8M in the prior-year period — down 14.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SLXNW's other current assets is now $1.5M (was $1.8M) — a 14.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Silexion Therapeutics - Warrants(14/08/2029) is outperforming or lagging.

Tracking SLXNW's other current assets over time shows whether Silexion Therapeutics - Warrants(14/08/2029) is scaling, shrinking, or reshaping that part of the business. The current reading is $1.5M That compares with $1.8M in the prior-year period — down 14.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has Silexion Therapeutics - Warrants(14/08/2029)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $1.5M) with ownership activity and broader fundamentals.